{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:09Z","timestamp":1790717169671,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01569-x","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:16:49Z","timestamp":1760627809000},"page":"659-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secukinumab Plus Upadacitinib for the Treatment of Severe Hidradenitis Suppurativa and Associated Immune-Mediated Comorbidities: A Case Series"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-6727","authenticated-orcid":false,"given":"Francisco Javier","family":"Melgosa Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Mart\u00ednez Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Galarreta Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Sanz-Motilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"5","key":"1569_CR1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1569_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ajd.14388","volume":"66","author":"J Frew","year":"2025","unstructured":"Frew J, Smith A, Penas PF, et al. Australasian hidradenitis suppurativa management guidelines. Australas J Dermatol. 2025;66(2):75\u201389.","journal-title":"Australas J Dermatol"},{"issue":"6","key":"1569_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1159\/000533370","volume":"239","author":"A Tsiogka","year":"2023","unstructured":"Tsiogka A, Liakou AI, Agiasofitou E, et al. Adalimumab-induced paradoxical psoriasis treated with biologics targeting the IL-17\/IL-23 axis in patients with hidradenitis suppurativa. Dermatology. 2023;239(6):937\u201341.","journal-title":"Dermatology"},{"issue":"6S","key":"1569_CR4","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jaad.2024.09.014","volume":"91","author":"D Jaguan","year":"2024","unstructured":"Jaguan D, Nguyen KT, Goldfarb N. Selective small molecule inhibitors for hidradenitis suppurativa: today and tomorrow. J Am Acad Dermatol. 2024;91(6S):S31\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1569_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/bjd\/ljae469","volume":"192","author":"AB Kimball","year":"2025","unstructured":"Kimball AB, Bechara FG, Badat A, et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week\u00a0104 results from the SUNSHINE and SUNRISE extension trial. Br J Dermatol. 2025;192(4):629\u201340.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1569_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.abd.2024.10.007","volume":"100","author":"R Bueno-Filho","year":"2025","unstructured":"Bueno-Filho R, Lorenzini D, Parra RS. Efficacy of upadacitinib in the management of atopic dermatitis, Crohn\u2019s disease, and hidradenitis suppurativa: one treatment, multiple indications. An Bras Dermatol. 2025;100(3):583\u20136.","journal-title":"An Bras Dermatol"},{"issue":"10","key":"1569_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/art.42926","volume":"76","author":"JT Merrill","year":"2024","unstructured":"Merrill JT, Tanaka Y, D\u2019Cruz D, et al. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase\u00a02 randomized controlled trial. Arthritis Rheumatol. 2024;76(10):1518\u201329.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1569_CR8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","volume":"92","author":"LS Ackerman","year":"2025","unstructured":"Ackerman LS, Schlosser BJ, Zhan T, et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase\u00a02, randomized, placebo-controlled study. J Am Acad Dermatol. 2025;92(6):1252\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"1569_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdcr.2024.12.008","volume":"56","author":"Z Islam","year":"2024","unstructured":"Islam Z, Choi S, Wang L, Andriano TM, Campton K. Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa. JAAD Case Rep. 2024;56:74\u20136.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"1569_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ijd.17512","volume":"64","author":"CA Carlos","year":"2025","unstructured":"Carlos CA, Tous-Romero F, Garc\u00eda-Donoso C, et al. Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series. Int J Dermatol. 2025;64(3):623\u20135.","journal-title":"Int J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01569-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:10Z","timestamp":1770190810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01569-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01569-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francisco Javier Melgosa Ramos has received honoraria and\/or travel grants and\/or has acted as an advisory board member for Novartis, Abbvie, Janssen Cilag, UCB, Lilly, LEO Pharma, L\u2019Oreal, Sanofi, Almirall, and Amgen. Antonio Martorell has received honoraria and\/or travel grants and\/or has acted as an advisory board member or principal investigator in clinical trials for Incyte, Moonlake, MSD, Novartis, Abbvie, Johnson\u2009&\u2009Johnson, UCB, Lilly, LEO Pharma, Takeda, Sanofi, Almirall, and Amgen. Esperanza Mart\u00ednez Ruiz, Marta Galarreta Pascual, and Virginia Sanz-Motilva have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments, and also in compliance with national regulations and ethical principles governing biomedical research in Spain. According to national legislation (Law 14\/2007 on Biomedical Research and the EU General Data Protection Regulation [GDPR] 2016\/679), research involving anonymized data may be exempt from requiring institutional review board (IRB) approval. In this case, as a result of the full anonymization of the data and because this manuscript describes a retrospective case series of three patients, formal approval from a research ethics committee was not required, in accordance with current Spanish legislation and institutional policies. The patients in this manuscript have given informed consent to the publication of their case details and photographs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}